Biologics, including TNF-α inhibitors (infliximab and adalimumab), IL-1β inhibitors (anakinra), and IL-6 inhibitors (tocilizumab and atlizumab), represent a prominent group of drugs used in the treatment of RA, but their administration may cause side effects and can interfere with the immune defense responses. Here, IL1B is linked to rheumatoid arthritis.